Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Clinical activity and immune correlates of glofitamab combined with tislelizumab in relapsed/refractory follicular lymphoma: A translational study

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXianming LiuHebei University of Engineering

Discussion

Loading...

Member takes

Implication

Single-center trial achieved 100% overall response rate and 83.3% complete remission in relapsed/refractory follicular lymphoma, suggesting potential for PD-1/PD-L1 engagement.

Key Points

  • Achieved 100% overall response rate with 83.3% complete remission in R/R follicular lymphoma patients, demonstrating substantial efficacy.
  • Analysis revealed significant minimal residual disease negativity observed in all complete remission patients via next-generation flow cytometry.
  • Investigations involved a fixed-duration regimen combining glofitamab and tislelizumab, highlighting a novel synergistic approach to treatment.
  • Results indicate a well-tolerated safety profile, with grade 1-2 cytokine release syndrome being the most common adverse event.

Cite This Study

Xianming Liu (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da0chttps://doi.org/10.1182/blood-2025-3595
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma2025 · 1 citations
  2. 2Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study2025
  3. 3Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  4. 4A chemo-free tumor microenvironment (TME) reshaping regimen combining glofitamab induces a high CR rate in relapsed/refractory diffuse large B cell lymphoma (DLBCL)2025
  5. 5Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study2025